Latest / DDReg Knowledge Capsule / Navigate German Nutraceutical & Novel Food Compliance

Transcript

Navigate German Nutraceutical & Novel Food Compliance · DDReg Knowledge Capsule

• 0:00
  Speaker 1: Welcome to the DD Reg Knowledge Capsule. So imagine you're
• 0:04
  Speaker 1: launching this, you know, this best-selling supplement in Europe's biggest market.
• 0:07
  Speaker 2: Right, Germany.
• 0:08
  Speaker 1: Exactly. You've spent millions on R & D, the branding
• 0:11
  Speaker 1: is done, distribution is set up. You submit your paperwork,
• 0:15
  Speaker 1: you get this official government receipt acknowledging your launch, and
• 0:19
  Speaker 1: you just start shipping.
• 0:20
  Speaker 2: Sounds like a success story so far. Right?
• 0:23
  Speaker 1: But then, like, six months later, you are facing a
• 0:26
  Speaker 1: catastrophic company-ending recall. Oh, yeah.
• 0:30
  Speaker 2: The nightmare scenario.
• 0:31
  Speaker 1: And not because your product is contaminated or anything, but
• 0:34
  Speaker 1: because your seemingly harmless natural plant extract is legally classified
• 0:39
  Speaker 1: by the European Union right alongside experimental lab-grown nanomaterials.
• 0:45
  Speaker 2: It is. It's terrifying. And the scariest part is that
• 0:48
  Speaker 2: it happens to well-intentioned companies all the time.
• 0:50
  Speaker 1: Just constantly, right? Yeah.
• 0:52
  Speaker 2: Simply because they fundamentally misunderstand how European food law actually
• 0:56
  Speaker 2: operates in practice.
• 0:57
  Speaker 1: Which is exactly our mission today. We are taking you
• 1:00
  Speaker 1: on a deep dive into a really comprehensive DD Reg
• 1:04
  Speaker 1: article that decodes this exact regulatory maze regarding nutraceutical registration
• 1:10
  Speaker 1: in Germany.
• 1:10
  Speaker 2: It's a very dense maze, yeah.
• 1:12
  Speaker 1: It really is. We're looking specifically at the complexities of
• 1:15
  Speaker 1: the EU novel food regulations. We really want to understand
• 1:19
  Speaker 1: why a familiar everyday health ingredient might legally be considered
• 1:23
  Speaker 1: this restricted novel food.
• 1:25
  Speaker 2: Right. And how companies can navigate that massive gap.
• 1:28
  Speaker 1: That fatal gap, honestly.
• 1:29
  Speaker 2: Between simply telling the government you're selling something and actually
• 1:33
  Speaker 2: having a legally marketable product.
• 1:35
  Speaker 1: Because that gap is essentially a graveyard for product launches.
• 1:38
  Speaker 1: I mean, if you don't understand the mechanisms of why
• 1:42
  Speaker 1: certain ingredients trigger alarms while others just don't, you are
• 1:45
  Speaker 1: flying entirely blind.
• 1:47
  Speaker 2: So let's start right at the edge of that graveyard.
• 1:50
  Speaker 2: The very first trap that companies fall into when they
• 1:52
  Speaker 2: target the German market Is this widespread illusion of approval?
• 1:56
  Speaker 1: Yes.
• 1:57
  Speaker 2: The notification illusion.
• 1:58
  Speaker 1: Right. It's this assumption that if you tell the government
• 2:01
  Speaker 1: about your product and the government hands you a receipt saying,
• 2:03
  Speaker 1: you know, thank you for telling us that you're totally
• 2:06
  Speaker 1: in the clear.
• 2:06
  Speaker 2: It is arguably the most dangerous misunderstanding in the entire
• 2:10
  Speaker 2: European supplement space.
• 2:12
  Speaker 1: Wow, really?
• 2:13
  Speaker 2: Oh, absolutely. So the baseline requirement in Germany under their
• 2:16
  Speaker 2: local food supplement laws, specifically Section 5 of the NEMVEH,
• 2:20
  Speaker 2: is that a manufacturer or an importer has to notify
• 2:24
  Speaker 2: the authorities.
• 2:24
  Speaker 1: The Federal Office of Consumer Protection and Food Safety, right?
• 2:28
  Speaker 2: Exactly, which we'll just call the BVL to save some breath.
• 2:30
  Speaker 2: Good call. So you have to submit a copy of
• 2:32
  Speaker 2: your product label to the BVL no later than the
• 2:35
  Speaker 2: time you first place the product on the market.
• 2:37
  Speaker 1: OK, let's unpack this, because to a rational person, if
• 2:40
  Speaker 1: you submit official paperwork and a label to a federal
• 2:43
  Speaker 1: consumer protection office and they give you a stamped delivery receipt.
• 2:47
  Speaker 2: In return, It feels like an endorsement. It really does.
• 2:49
  Speaker 1: It feels like a green light. It's like sending a
• 2:51
  Speaker 1: registered letter to the government. Getting the delivery receipt proves
• 2:54
  Speaker 1: you mailed it to them and they accepted it.
• 2:56
  Speaker 2: It proves you mailed it. Certainly. But to build on
• 2:59
  Speaker 2: that analogy, just because the government signs for your registered
• 3:02
  Speaker 2: letter doesn't mean they grant you immunity for whatever is
• 3:05
  Speaker 2: written inside it.
• 3:06
  Speaker 1: That makes sense.
• 3:07
  Speaker 2: I mean, if you mailed them a written confession to
• 3:09
  Speaker 2: tax fraud, that delivery receipt isn't an approval of your actions.
• 3:13
  Speaker 1: Definitely not. Right.
• 3:15
  Speaker 2: So when a company receives that confirmation from the BVL,
• 3:18
  Speaker 2: all it means is they have checked a mandatory procedural box.
• 3:22
  Speaker 1: Ah, okay.
• 3:23
  Speaker 2: The BVL itself explicitly states that the receipt does not
• 3:26
  Speaker 2: certify the product's marketability, or its safety for that matter.
• 3:30
  Speaker 1: Wait, so the Federal Consumer Protection Office is basically just
• 3:33
  Speaker 1: operating as a filing cabinet at that stage?
• 3:35
  Speaker 2: Essentially, yes.
• 3:36
  Speaker 1: What does actually certify marketability, then?
• 3:39
  Speaker 2: Well, that is the ultimate burden of the company. The
• 3:42
  Speaker 2: BVL notification merely asks... Did you log your entry into
• 3:46
  Speaker 2: the market? But a marketability assessment asks a much more
• 3:50
  Speaker 2: rigorous set of questions.
• 3:51
  Speaker 1: Like what?
• 3:52
  Speaker 2: Well, does the molecular formulation comply with general EU food law?
• 3:57
  Speaker 2: Are your marketing claims legally substantiated? Are you under the
• 4:00
  Speaker 2: strict maximum levels for specific contaminants?
• 4:03
  Speaker 1: Okay, yeah, lots of hurdles.
• 4:05
  Speaker 2: And the biggest hurdle of all, does your botanical extract
• 4:08
  Speaker 2: trigger a novel food assessment?
• 4:09
  Speaker 1: And this brings us right to the core of the issue.
• 4:12
  Speaker 1: If that BVL receipt doesn't grant you the legal right
• 4:15
  Speaker 1: to market the product, we have to look at what
• 4:17
  Speaker 1: actually dictates whether an ingredient is legally permitted to be
• 4:20
  Speaker 1: sold as food in the first place.
• 4:22
  Speaker 2: Exactly.
• 4:22
  Speaker 1: Which brings us to what I can only really describe
• 4:25
  Speaker 1: as a legal fossil record.
• 4:27
  Speaker 2: Yeah, that's a good way to look at it. The
• 4:28
  Speaker 2: foundational law governing European supplement ingredients anchors itself to a
• 4:33
  Speaker 2: very specific, inflexible date in the past.
• 4:36
  Speaker 1: Regulation EU 2015-2283, right? That's the one.
• 4:40
  Speaker 2: And the date is May 15, 1997. Right.
• 4:43
  Speaker 1: Which is wild. So to understand if your ingredient is
• 4:46
  Speaker 1: a novel food, which if it is, usually means you
• 4:48
  Speaker 1: are in for a mountain of regulatory pain and really
• 4:52
  Speaker 1: expensive safety assessments.
• 4:54
  Speaker 2: Oh, incredibly expensive.
• 4:55
  Speaker 1: Yeah. You have to prove it was consumed to a
• 4:57
  Speaker 1: significant degree by humans in the EU before that exact
• 5:01
  Speaker 1: date in 1997.
• 5:02
  Speaker 2: Correct. But the sources make a massive distinction here about
• 5:06
  Speaker 2: the type of history you actually need to prove.
• 5:09
  Speaker 1: Right, you need historical proof of food use, not medicinal use,
• 5:12
  Speaker 1: food use. Yes.
• 5:14
  Speaker 2: The European framework draws an incredibly strict, like, bright-line boundary
• 5:18
  Speaker 2: between medicinal history and food history.
• 5:21
  Speaker 1: I have to play the skeptical voice for the listener here, though,
• 5:24
  Speaker 1: because biologically this sounds completely irrational.
• 5:28
  Speaker 2: How so?
• 5:29
  Speaker 1: Well, if a specific plant was used as a highly effective,
• 5:32
  Speaker 1: highly traditional cough remedy in Germany for, like, 300 years,
• 5:37
  Speaker 1: and we have medical texts saying proving people safely ingested it.
• 5:40
  Speaker 2: Right.
• 5:41
  Speaker 1: Are you telling me that historical evidence is totally useless
• 5:44
  Speaker 1: for a food supplement application today?
• 5:47
  Speaker 2: What's fascinating here is, legally speaking, yes, it is largely
• 5:51
  Speaker 2: useless for establishing a history of food consumption.
• 5:54
  Speaker 1: Wait, really?
• 5:55
  Speaker 2: Useless? Yeah, you have to understand the regulatory logic behind it.
• 5:59
  Speaker 2: Ingesting a targeted, potent botanical to cure an acute illness
• 6:03
  Speaker 2: over a short period of time is biologically and legally
• 6:07
  Speaker 2: distinct From consuming something daily as a food.
• 6:10
  Speaker 1: Or a dietary supplement.
• 6:12
  Speaker 2: Exactly. To maintain normal, long-term health.
• 6:15
  Speaker 1: Ah, because the risk profile changes if you're taking it
• 6:18
  Speaker 1: every single morning with your coffee versus just taking it
• 6:21
  Speaker 1: for three days when you have the flu.
• 6:23
  Speaker 2: Exactly. The toxicological risks accumulate differently. So if you want
• 6:27
  Speaker 2: to clear that 1997 evolutionary cutoff for a food supplement,
• 6:31
  Speaker 2: you cannot bring medical records to the table.
• 6:34
  Speaker 1: What do you bring then?
• 6:35
  Speaker 2: You need published literature. showing nutritional use. You need commercial
• 6:40
  Speaker 2: documentation from the 1980s or 90s.
• 6:43
  Speaker 1: Like what, old restaurant menus?
• 6:45
  Speaker 2: Literally, yes. Old restaurant menus, import invoices, historical cookbooks.
• 6:50
  Speaker 1: You literally have to prove that somebody's grandma made a
• 6:53
  Speaker 1: daily soup out of it, not a potent cough syrup.
• 6:56
  Speaker 2: Basically, yeah. You need evidence from national or regional markets
• 7:00
  Speaker 2: showing actual, widespread, everyday food use prior to May 1997.
• 7:04
  Speaker 2: That is so specific. It is. And the nuance here
• 7:08
  Speaker 2: is critical. Even if a substance was used exclusively in
• 7:12
  Speaker 2: food supplements before 1997, the regulation places specific restrictions on
• 7:17
  Speaker 2: it if you suddenly decide you want to put that
• 7:18
  Speaker 2: same ingredient into a regular food matrix.
• 7:21
  Speaker 1: Like putting it in a fortified beverage or a protein
• 7:24
  Speaker 1: bar or something.
• 7:25
  Speaker 2: Exactly. The context of consumption is everything.
• 7:28
  Speaker 1: Okay, so let's say a company does the historical digging.
• 7:31
  Speaker 1: They hire researchers, they find the old 1995 commercial catalogs,
• 7:36
  Speaker 1: They dig up all those import invoices.
• 7:38
  Speaker 2: Let's paperwork.
• 7:39
  Speaker 1: Mountains of it. And they prove their botanical plant was
• 7:43
  Speaker 1: widely eaten as food in France and Germany before 1997.
• 7:46
  Speaker 1: They wipe the sweat from their brow, thinking their R
• 7:49
  Speaker 1: & D budget is totally safe.
• 7:51
  Speaker 2: But they aren't safe.
• 7:52
  Speaker 1: No, because just because a source plant passes the 1997
• 7:56
  Speaker 1: test doesn't mean everything made from that plant is legal.
• 8:01
  Speaker 2: And this is where modern science aggressively outpaces the assumptions
• 8:04
  Speaker 2: of product developers. The source plant is merely the biological
• 8:09
  Speaker 2: starting line.
• 8:10
  Speaker 1: Here's where it gets really interesting. Because the botanical ingredient
• 8:15
  Speaker 1: basically acts as a shapeshifter, depending on how you treat it.
• 8:19
  Speaker 1: The sources use echinacea in 2026 as the prime example.
• 8:23
  Speaker 2: Right, echinacea.
• 8:24
  Speaker 1: Echinacea has been around forever. We all know it. But
• 8:27
  Speaker 1: its regulatory status changes completely based on modern processing, the
• 8:32
  Speaker 1: extraction methods, the specific plant part used, and even the
• 8:35
  Speaker 1: final chemical composition.
• 8:38
  Speaker 2: To put it bluntly, the law doesn't just look at
• 8:39
  Speaker 2: the genus and species of the plant. It looks at
• 8:42
  Speaker 2: the specific molecule you are actually handing to the consumer.
• 8:46
  Speaker 1: So if I'm a formulator, it's like saying, just because
• 8:51
  Speaker 1: humans have safely eaten boiled potatoes for centuries... A completely new, hyper-concentrated,
• 8:56
  Speaker 1: lab-fermented potato nanomaterial is automatically safe to eat.
• 9:00
  Speaker 2: Right. Simply because marketing decided to call it ate potato extract.
• 9:05
  Speaker 1: Exactly.
• 9:06
  Speaker 2: It's a great analogy, but it's actually even stricter than
• 9:09
  Speaker 2: that in reality. It's not just about extreme sci-fi nanomaterials.
• 9:14
  Speaker 2: Even using a simple modern solvent on that potato could
• 9:17
  Speaker 2: radically change its safety profile.
• 9:19
  Speaker 1: Because it pulls out different stuff. Exactly.
• 9:20
  Speaker 2: Exactly. Traditional hot water extraction, like making a tea, mostly
• 9:25
  Speaker 2: pulls out water-soluble compounds. But if you take that same
• 9:29
  Speaker 2: plant today and run it through a supercritical CO2 extraction?
• 9:32
  Speaker 1: Or like harsh ethanol solvents? Yeah.
• 9:36
  Speaker 2: You might be pulling out fat-soluble compounds, heavy metals, or
• 9:39
  Speaker 2: novel alkaloids that the human digestive system has just never
• 9:42
  Speaker 2: encountered in those high concentrations.
• 9:44
  Speaker 1: Because the modern extraction method literally changes what molecules end
• 9:49
  Speaker 1: up in the jar.
• 9:49
  Speaker 2: It fundamentally alters the resulting food. It affects the nutritional value,
• 9:54
  Speaker 2: how human metabolism processes it, and the concentration of undesirable
• 9:58
  Speaker 2: toxic substances. Wow. The novel food law specifically flags foods
• 10:03
  Speaker 2: resulting from production processes that were not used in the
• 10:06
  Speaker 2: EU before 1997.
• 10:07
  Speaker 1: So back to your echinacea example. The sources note that
• 10:12
  Speaker 1: if we look at the definitive EU lists today in 2026,
• 10:16
  Speaker 1: We see authorized novel foods like Echinacea angostifolia extract and
• 10:20
  Speaker 1: Echinacea purpurea extract.
• 10:22
  Speaker 2: Right.
• 10:23
  Speaker 1: But they are derived specifically from cell cultures.
• 10:26
  Speaker 2: Yes, lab-grown plant cells.
• 10:29
  Speaker 1: Why are cell cultures automatically treated differently than just, you know,
• 10:32
  Speaker 1: growing the plant in the dirt?
• 10:33
  Speaker 2: Well, because lab-grown plant cells bypass the environmental stressors a
• 10:37
  Speaker 2: real plant faces in nature.
• 10:39
  Speaker 1: Like the weather, soil microbes, pests, that kind of thing?
• 10:43
  Speaker 2: Exactly. Without those natural stressors, The lab-grown cells often produce
• 10:47
  Speaker 2: an entirely different profile of active compounds and secondary metabolites.
• 10:52
  Speaker 1: Oh, that makes sense.
• 10:53
  Speaker 2: They might lack certain beneficial compounds or wildly overproduce others.
• 10:57
  Speaker 2: So extracting a compound from a lab-grown cell culture in
• 11:00
  Speaker 2: 2026 is a biochemical universe away from steeping dried echinacea
• 11:05
  Speaker 2: roots in hot water in 1996.
• 11:08
  Speaker 1: Which means a company cannot just ride the coattails of
• 11:11
  Speaker 1: a basic plant's long history of If their processing method
• 11:15
  Speaker 1: is fundamentally modern.
• 11:16
  Speaker 2: They cannot. A botanical extract assessment must be conducted at
• 11:20
  Speaker 2: the level of the actual final ingredient being placed on
• 11:23
  Speaker 2: the market.
• 11:24
  Speaker 1: Man, if you're a formulator listening to this, this is
• 11:26
  Speaker 1: where your budget gets totally obliterated.
• 11:28
  Speaker 2: Oh, absolutely.
• 11:29
  Speaker 1: You can't just buy a standard extract off a supplier's shelf,
• 11:33
  Speaker 1: slap a familiar name on the label, and assume you're
• 11:35
  Speaker 1: legally compliant. You have to know the exact biochemical preparation.
• 11:39
  Speaker 2: And when a company realizes this, what do they do?
• 11:41
  Speaker 1: They naturally go looking for a cheat sheet.
• 11:44
  Speaker 2: Exactly.
• 11:45
  Speaker 1: They go to the European databases to find out what's allowed.
• 11:48
  Speaker 1: But the sources highlight a massive pitfall here regarding how
• 11:51
  Speaker 1: these databases actually function.
• 11:54
  Speaker 2: Because there is a critical difference between a guidebook and
• 11:57
  Speaker 2: the actual binding law. Companies constantly confuse the novel food
• 12:02
  Speaker 2: catalog with the union list.
• 12:04
  Speaker 1: Okay, let's break those down. The novel food catalog is
• 12:08
  Speaker 1: described by the European Commission as providing... quote, non-binding orientation.
• 12:13
  Speaker 1: It lists various plants, animals, algae, microorganisms.
• 12:17
  Speaker 2: But the catalog is essentially just a shared notepad among
• 12:19
  Speaker 2: EU member states.
• 12:21
  Speaker 1: A shared notepad.
• 12:22
  Speaker 2: Yeah, it just records what different national authorities currently think
• 12:25
  Speaker 2: about the status of these ingredients based on past discussions.
• 12:29
  Speaker 2: It is explicitly non-exhaustive and non-binding.
• 12:32
  Speaker 1: Whereas the union list is the actual law. It is
• 12:36
  Speaker 1: the definitive, legally binding ledger of officially authorized novel foods
• 12:41
  Speaker 1: containing their exact conditions of use, labeling requirements, strict chemical specifications. Right.
• 12:47
  Speaker 2: If you are an authorized novel food, you are on
• 12:50
  Speaker 2: the union list.
• 12:51
  Speaker 1: So wait, if the catalog is just a non-exhaustive notepad,
• 12:55
  Speaker 1: this creates a massive blind spot.
• 12:57
  Speaker 2: A huge one.
• 12:58
  Speaker 1: A company might look at their new botanical extract, search
• 13:01
  Speaker 1: the novel food catalog, find absolutely zero mention of it
• 13:04
  Speaker 1: and think, hey, nobody has flagged this. It's not in
• 13:06
  Speaker 1: the catalog. Therefore, it's not novel. We're in the clear.
• 13:09
  Speaker 2: And that missing entry is a massive red flag, not
• 13:12
  Speaker 2: a green light.
• 13:13
  Speaker 1: Wow. Yeah.
• 13:13
  Speaker 2: The absence of an ingredient from that catalog does not
• 13:16
  Speaker 2: mean it is traditional and safe. It usually just means
• 13:19
  Speaker 2: nobody has formally asked the member states to evaluate it yet.
• 13:22
  Speaker 1: Wait, so the catalog is basically a mirage. A company
• 13:25
  Speaker 1: could spend millions on product development thinking they are in
• 13:28
  Speaker 1: the clear just because nobody in the government has bothered
• 13:30
  Speaker 1: to flag their specific ingredient yet.
• 13:33
  Speaker 2: Sadly, yes.
• 13:34
  Speaker 1: How is the burden of proof entirely on the company
• 13:37
  Speaker 1: if the government's own orientation database is incomplete?
• 13:40
  Speaker 2: Because the market moves infinitely faster than the regulators. Food technology,
• 13:44
  Speaker 2: extraction methods, global ingredient sourcing, they evolve daily. True. It
• 13:49
  Speaker 2: is physically impossible for the European Commission... to pre-assess every
• 13:53
  Speaker 2: possible botanical derivative before it exists. Therefore, the default legal
• 13:58
  Speaker 2: stance is unsafe until proven traditional or formally authorized.
• 14:02
  Speaker 1: You don't get a free pass just because the regulators
• 14:04
  Speaker 1: haven't noticed your specific extraction method yet.
• 14:07
  Speaker 2: Exactly.
• 14:08
  Speaker 1: So what does a company do if they are stuck
• 14:10
  Speaker 1: in the gray area? They have the old documents, but
• 14:13
  Speaker 1: their extraction method is slightly modernized. Not radically different, but
• 14:16
  Speaker 1: different enough to cause anxiety.
• 14:19
  Speaker 2: They should never just guess and launch. EU law, specifically
• 14:22
  Speaker 2: Regulation EU 2018-456, provides a formal mechanism for this exact scenario. Okay, good.
• 14:29
  Speaker 2: You have the right to formally consult the competent authority
• 14:32
  Speaker 2: of the member state where you intend to launch first.
• 14:35
  Speaker 1: So if you're launching in Germany, you go directly to
• 14:37
  Speaker 1: the BVL and ask them to make a ruling?
• 14:39
  Speaker 2: Yes. You don't just send an email, though.
• 14:41
  Speaker 1: I imagine not.
• 14:42
  Speaker 2: You submit a heavily supported technical dossier detailing your ingredient's
• 14:46
  Speaker 2: exact identity, its molecular composition... the complete manufacturing process, and
• 14:52
  Speaker 2: all your historical use data.
• 14:54
  Speaker 1: And then what?
• 14:54
  Speaker 2: The BVL reviews the science and provides a formal, legally
• 14:58
  Speaker 2: binding determination on whether it is a novel food or not.
• 15:01
  Speaker 1: Which takes time, obviously, but it's infinitely better than launching
• 15:05
  Speaker 1: blind and having your inventory seized.
• 15:07
  Speaker 2: Much better.
• 15:08
  Speaker 1: And to really ground how volatile this regulatory environment is,
• 15:11
  Speaker 1: we need to look at how the European Commission is
• 15:13
  Speaker 1: treating high-profile ingredients right now, in 2026. The sources heavily
• 15:18
  Speaker 1: feature CBD.
• 15:19
  Speaker 2: CBD perfectly illustrates how complex and unforgiving this landscape is.
• 15:23
  Speaker 1: Because CBD feels ubiquitous, consumers see it everywhere. But the
• 15:28
  Speaker 1: regulatory reality behind the scenes is incredibly turbulent.
• 15:32
  Speaker 2: Oh, completely.
• 15:33
  Speaker 1: The sources point out that in 2026, the commission has
• 15:37
  Speaker 1: been actively terminating individual CBD-related novel food authorization procedures without
• 15:42
  Speaker 1: adding them to the union list.
• 15:44
  Speaker 2: And this confuses a lot of observers. Companies look at
• 15:47
  Speaker 2: the sheer volume of regulatory activity around CBD. The headlines,
• 15:52
  Speaker 2: the ongoing consultations, the dozens of applications in the pipeline.
• 15:56
  Speaker 1: And they interpret that bureaucratic noise as tacit approval.
• 16:00
  Speaker 2: Exactly. They assume that because everyone is talking about CBD,
• 16:04
  Speaker 2: their specific CBD isolate must eventually be fine.
• 16:07
  Speaker 1: But repeated regulatory activity does not equal blanket authorization. Why
• 16:12
  Speaker 1: is the commission terminating these applications instead of just approving
• 16:16
  Speaker 1: CBD across the board?
• 16:17
  Speaker 2: Well, if we connect this to the bigger picture, it
• 16:20
  Speaker 2: goes back to the mechanism of extraction and composition we
• 16:23
  Speaker 2: discussed earlier.
• 16:24
  Speaker 1: The shapeshifter concept. Right.
• 16:26
  Speaker 2: An application proving the safety of a 99% pure CBD
• 16:29
  Speaker 2: isolate cannot legally or scientifically cover a 50% CBD broad-spectrum
• 16:34
  Speaker 2: oil that contains dozens of other cannabinoids and terpenes.
• 16:38
  Speaker 1: Because the metabolic pathways in the human body and the
• 16:41
  Speaker 1: toxicological risks differ completely between those two substances.
• 16:45
  Speaker 2: Precisely. They shut these applications down because the safety science
• 16:49
  Speaker 2: doesn't universally transfer. The novel food assessment is not a
• 16:53
  Speaker 2: static exercise based on the acronym CBD.
• 16:56
  Speaker 1: Right.
• 16:57
  Speaker 2: The commission evaluates the precise substance, the source material, the
• 17:01
  Speaker 2: extraction solvent, and the intended use. If the specific scientific
• 17:05
  Speaker 2: evidence for a specific preparation isn't bulletproof, the application is terminated.
• 17:11
  Speaker 1: It's a constantly moving target. The sources also mention L-theanine
• 17:15
  Speaker 1: as another ingredient that has recently been flagged as a
• 17:17
  Speaker 1: novel food in the consultation records.
• 17:19
  Speaker 2: Yes.
• 17:19
  Speaker 1: It just proves that you cannot rely on what the
• 17:21
  Speaker 1: market looked like two years ago. You have to assess
• 17:23
  Speaker 1: the data today for your exact molecule.
• 17:27
  Speaker 2: Which brings us to the ultimate question for any brand
• 17:29
  Speaker 2: trying to navigate this.
• 17:30
  Speaker 1: Right. So what does this all mean? If you are
• 17:34
  Speaker 1: a brand owner trying to launch a health product, or
• 17:36
  Speaker 1: you're a formulator staring at a spreadsheet of ingredients, How
• 17:39
  Speaker 1: do you actually survive this process and enter the German
• 17:42
  Speaker 1: market legally?
• 17:43
  Speaker 2: Well, the sources outline a seven-step framework, but it's really
• 17:47
  Speaker 2: about shifting your entire operational mindset. It's a gauntlet with
• 17:51
  Speaker 2: distinct phases.
• 17:52
  Speaker 1: It is a playbook that requires working backwards, essentially.
• 17:56
  Speaker 2: Yes. Before you even look at German compliance laws, you
• 17:59
  Speaker 2: have to initiate phase one, interrogating the molecule itself.
• 18:03
  Speaker 1: Which means defining the ingredient far beyond its marketing name.
• 18:07
  Speaker 2: You must confirm the exact scientific species, the specific plant
• 18:12
  Speaker 2: part used, whether it's the root, leaf, or stem, the
• 18:15
  Speaker 2: precise preparation, the processing method, the solvents used, and the
• 18:19
  Speaker 2: final chemical specification.
• 18:21
  Speaker 1: You basically have to know the chemical blueprint.
• 18:23
  Speaker 2: Exactly.
• 18:25
  Speaker 1: Then you move to phase two, the historical audit. This
• 18:28
  Speaker 1: is where you determine the intended use. Who is eating
• 18:31
  Speaker 1: this and how much? And then cross-reference that against the
• 18:35
  Speaker 1: EU databases.
• 18:36
  Speaker 2: Right. You check the binding union list and the non-binding
• 18:39
  Speaker 2: novel food catalog.
• 18:41
  Speaker 1: Keeping in mind that an entry for a hot water
• 18:44
  Speaker 1: extract does not cover your modern CO2 extract.
• 18:48
  Speaker 2: Never. And if you aren't explicitly authorized, you dig into
• 18:51
  Speaker 2: the legal fossil record. You must gather the evidence of
• 18:55
  Speaker 2: significant EU food consumption before May 15th, 1997.
• 18:59
  Speaker 1: Ensuring your historical evidence matches the exact biological form you
• 19:03
  Speaker 1: defined in phase one. Yes.
• 19:05
  Speaker 2: You must prove your modern extraction or fermentation process didn't
• 19:09
  Speaker 2: inadvertently create a novel substance.
• 19:11
  Speaker 1: And only after you've survived the molecular interrogation and the
• 19:15
  Speaker 1: historical audit do you enter phase three, broader local compliance.
• 19:19
  Speaker 2: Because you're entering Germany.
• 19:20
  Speaker 1: Right. So you assess local rules regarding labeling, health claims,
• 19:24
  Speaker 1: pesticide limits. and ensuring your product hasn't crossed the legal
• 19:27
  Speaker 1: borderline into being classified as an unapproved medicinal drug.
• 19:32
  Speaker 2: And if there is any remaining uncertainty at this stage
• 19:34
  Speaker 2: about whether your extraction method altered the ingredient status, you
• 19:38
  Speaker 2: pause everything.
• 19:39
  Speaker 1: You don't just guess.
• 19:40
  Speaker 2: No guessing. You utilize the formal BVL consultation process to
• 19:44
  Speaker 2: get a ruling.
• 19:45
  Speaker 1: Which finally brings us to the very last phase, the notification.
• 19:50
  Speaker 2: Exactly. Submitting the BVL notification is the very last step
• 19:53
  Speaker 2: of the entire journey.
• 19:55
  Speaker 1: That is the ultimate takeaway here. Treating that BVL notification
• 19:59
  Speaker 1: receipt as your first step or as proof of approval
• 20:02
  Speaker 1: is a massive structural mistake.
• 20:04
  Speaker 2: A very expensive mistake. Yeah.
• 20:06
  Speaker 1: It should be the absolute last thing you do. executed
• 20:08
  Speaker 1: only after the exact regulatory identity of the ingredient is
• 20:12
  Speaker 1: fully vetted. You only notify the government you are entering
• 20:15
  Speaker 1: the market once you already know with absolute certainty that
• 20:19
  Speaker 1: you are legally compliant.
• 20:21
  Speaker 2: And navigating that gauntlet is exactly why groups like DD
• 20:24
  Speaker 2: Reg exist. They step in before a company commits to
• 20:27
  Speaker 2: a formulation.
• 20:28
  Speaker 1: Which is smart.
• 20:29
  Speaker 2: They conduct the gap analyses, review the complex botanical extraction data,
• 20:33
  Speaker 2: hunt down the necessary historical use evidence, and manage those
• 20:36
  Speaker 2: highly technical BVL consultations.
• 20:39
  Speaker 1: So they basically take the guesswork out of it. Right.
• 20:42
  Speaker 2: They ensure that by the time you finally hit submit
• 20:45
  Speaker 2: on that notification, your product is genuinely legally marketable.
• 20:49
  Speaker 1: Because launching with just a receipt and hoping for the
• 20:52
  Speaker 1: best is a gamble no company can afford to lose.
• 20:55
  Speaker 1: So to summarize the core lesson of this deep dive,
• 20:58
  Speaker 1: market entry in Germany requires proving the exact preparation-specific history
• 21:04
  Speaker 1: of your ingredient prior to to May 1997. The source
• 21:08
  Speaker 1: plant's history is not enough. Your extraction method dictates the
• 21:12
  Speaker 1: legal reality. And a simple delivery receipt from the government
• 21:16
  Speaker 1: will absolutely not save you from a novel food violation.
• 21:19
  Speaker 2: This raises an important question for the future, though.
• 21:21
  Speaker 1: Oh.
• 21:22
  Speaker 2: Well, we are sitting here in 2026, analyzing authorized extracts
• 21:26
  Speaker 2: derived from lab-grown cell cultures. If our extraction technologies, our
• 21:31
  Speaker 2: precision fermentation processes, and cellular agriculture capabilities are evolving so
• 21:36
  Speaker 2: much faster than our regulatory frameworks. What happens in a
• 21:40
  Speaker 2: few decades?
• 21:41
  Speaker 1: That's a good point.
• 21:41
  Speaker 2: When we start consuming entirely synthetic lab-grown botanicals on a
• 21:45
  Speaker 2: massive everyday scale. Will a regulation anchored to a single
• 21:49
  Speaker 2: day in the past, May 15th, 1997, eventually become completely
• 21:53
  Speaker 2: obsolete in a world of engineered nutrition?
• 21:56
  Speaker 1: Wow, that is a wild thought to leave on. The
• 21:58
  Speaker 1: further we get from 1997, the harder it will be
• 22:01
  Speaker 1: to tie the food of the future to the food
• 22:03
  Speaker 1: of the past at a molecular level. Thank you for
• 22:06
  Speaker 1: joining us on this deep dive. The next time you
• 22:08
  Speaker 1: pick up a supplement and look at the label, remember,
• 22:11
  Speaker 1: getting that product into your hands wasn't just a matter
• 22:13
  Speaker 1: of mixing ingredients in a vat. It was about surviving
• 22:16
  Speaker 1: the murky waters of regulatory history and molecular scrutiny. Keep
• 22:21
  Speaker 1: questioning what you consume, and we will catch you on
• 22:23
  Speaker 1: the next one.